Sandbox/thy10: Difference between revisions
< Sandbox
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
{{thymoma}} | {{thymoma}} | ||
== | ==Approach to Thymoma and Thymic Carcinoma== | ||
{{familytree/start}} | {{familytree/start}} | ||
| Line 22: | Line 22: | ||
<B><small>[[Sandbox/thy10#ABC|Return to top]]</small></B> | <B><small>[[Sandbox/thy10#ABC|Return to top]]</small></B> | ||
{| {{table}} | |||
| align="center" style="background:#f0f0f0;" colspan=2|'''FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS''' | |||
| align="center" style="background:#f0f0f0;"|'''SECOND-LINE CHEMOTHERAPY''' | |||
|- | |||
| '''CAP''' (preferred for thymoma) <BR> * Cisplatin 50 mg/m² IV day 1 <BR> * Doxorubicin 50 mg/m² IV day 1 <BR> * Cyclophosphamide 500 mg/m² IV day 1 <BR> Administered every 3 weeks|| '''PE''' <BR> * Cisplatin 60 mg/m² IV day 1 <BR> *Etoposide 120 mg/m²/d IV days 1 -3 <BR> Administered every 3 weeks||rowspan=3 valign=top|Etoposide <BR> Ifosfamide <BR> Pemetrexed <BR> Octreotide (including LAR) + prednisone <BR> 5-FU and leucovirin <BR> Gemcitabine <BR> Paclitaxel | |||
|- | |||
| '''CAP with Prednisone''' <BR> * Cisplatin 30 mg/m² IV days 1-3 <BR> * Doxorubicin 20 mg/m²/d <BR> IV continuous infusion on days 1 to 3 <BR> * Cyclophosphamide 500 mg/m² IV on day 1 <BR> * Prednisone 100 mg/day on days 1-5 <BR> Administered every 3 weeks||'''VIP''' <BR> * Etoposide 75 mg/m² on days 1-4 <BR>* Ifosfamide 1.2 g/m² on days 1-4 <BR> * Cisplatin 20 mg/m² on days 1-4 <BR> Administered every 3 weeks | |||
|- | |||
| '''ADOC''' <BR> * Cisplatin 50 mg/m² IV day 1 <BR> * Doxorubicin 40 mg/m² IV day 1 <BR> * Vincristine 0.6 mg/m² IV day 3 <BR> * Cyclophosphamide 700 mg/m² IV day 4 <BR> Administered every 3 weeks || '''Carboplatin/Paclitaxel''' (preferred for Thymic Carcinoma) <BR>* Carboplatin AUC 6 <BR> * Paclitaxel 225 mg/m² <BR> Administered every 3 weeks | |||
|- | |||
|} | |||
====Radiation Dose==== | ====Radiation Dose==== | ||
Revision as of 20:57, 27 February 2014
|
Thymoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Sandbox/thy10 On the Web |
|
American Roentgen Ray Society Images of Sandbox/thy10 |
Approach to Thymoma and Thymic Carcinoma
Thymoma or Thymic Carcinoma | |||||||||||||||||||||||||||||||||||||||
Locally Advanced | Solitary Metastasis | Distant metastasis | |||||||||||||||||||||||||||||||||||||
Surgery | |||||||||||||||||||||||||||||||||||||||
Re-evaluate for surgery | Chemotherapy or RT | ||||||||||||||||||||||||||||||||||||||
Resectable | Unresectable | ||||||||||||||||||||||||||||||||||||||
Surgery ± Postoperative RT | |||||||||||||||||||||||||||||||||||||||
Chemotherapy Regimens
| FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS | SECOND-LINE CHEMOTHERAPY | |
| CAP (preferred for thymoma) * Cisplatin 50 mg/m² IV day 1 * Doxorubicin 50 mg/m² IV day 1 * Cyclophosphamide 500 mg/m² IV day 1 Administered every 3 weeks |
PE * Cisplatin 60 mg/m² IV day 1 *Etoposide 120 mg/m²/d IV days 1 -3 Administered every 3 weeks |
Etoposide Ifosfamide Pemetrexed Octreotide (including LAR) + prednisone 5-FU and leucovirin Gemcitabine Paclitaxel |
| CAP with Prednisone * Cisplatin 30 mg/m² IV days 1-3 * Doxorubicin 20 mg/m²/d IV continuous infusion on days 1 to 3 * Cyclophosphamide 500 mg/m² IV on day 1 * Prednisone 100 mg/day on days 1-5 Administered every 3 weeks |
VIP * Etoposide 75 mg/m² on days 1-4 * Ifosfamide 1.2 g/m² on days 1-4 * Cisplatin 20 mg/m² on days 1-4 Administered every 3 weeks | |
| ADOC * Cisplatin 50 mg/m² IV day 1 * Doxorubicin 40 mg/m² IV day 1 * Vincristine 0.6 mg/m² IV day 3 * Cyclophosphamide 700 mg/m² IV day 4 Administered every 3 weeks |
Carboplatin/Paclitaxel (preferred for Thymic Carcinoma) * Carboplatin AUC 6 * Paclitaxel 225 mg/m² Administered every 3 weeks | |
Radiation Dose
- A dose of 60-70 Gy should be given to patients with unresectable disease.
- For adjuvant treatment, the radiation dose consists of 45-50 Gy for clear/close margins and 54 Gy for microscopically positive resection margins. A total dose of 60 Gy and above should be given to patients with gross residual disease (similar to patients with unresectable disease), when conventional fractionation (1.8 to 2.0 Gy per daily fraction) is applied.